BACKGROUND: In a study of childhood acute lymphoblastic leukemia (CoALL 06-97 study), the in vitro sensitivity of the patients' cells to prednisolone, vincristine and asparaginase was introduced as a new additional risk parameter for treatment stratification. In parallel in vivo treatment response was assessed by determining the presence and extent of minimal residual disease in a subset of patients (n=224). Here we report the long-term impact of in vitro sensitivity-based risk stratification according to survival and compare the results of in vitro sensitivity with in vivo response. DESIGN AND METHODS: Patients with a sensitive in vitro profile were treated with a reduced intensity protocol (n=167) whereas patients defined as low risk according to conventional parameters but with a resistant in vitro profile were given intensified therapy (n=47). RESULTS: At a median follow-up of 6.8 years event-free survival was 0.80±0.03 for patients with a sensitive profile, 0.73±0.03 for those with an intermediate profile and 0.67±0.08 for those with a resistant profile (P=0.015). Overall, the treatment results of the cases stratified according to in vitro sensitivity were similar to those of the historical control group stratified based on conventional risk factors. Minimal residual disease at the end of induction was a strong predictor of outcome in B-precursor and T-cell acute lymphoblastic leukemia. There was no correlation between in vitro and in vivo treatment response in B-precursor leukemia (Spearman's r=0.13; P=0.15) in contrast to T-cell acute lymphoblastic leukemia (Spearman's r=0.63; P<0.001) CONCLUSIONS: A moderate reduction in treatment intensity for patients with a sensitive in vitro profile was possible without jeopardizing treatment outcome. However, in vitro drug testing was affected by a decrease in risk predictive power over time and was not correlated with in vivo assessment of minimal residual disease in B-precursor acute lymphoblastic leukemia. It was, therefore, abandoned in favor of the assessment of in vivo response in subsequent CoALL trials.
BACKGROUND: In a study of childhood acute lymphoblastic leukemia (CoALL 06-97 study), the in vitro sensitivity of the patients' cells to prednisolone, vincristine and asparaginase was introduced as a new additional risk parameter for treatment stratification. In parallel in vivo treatment response was assessed by determining the presence and extent of minimal residual disease in a subset of patients (n=224). Here we report the long-term impact of in vitro sensitivity-based risk stratification according to survival and compare the results of in vitro sensitivity with in vivo response. DESIGN AND METHODS: Patients with a sensitive in vitro profile were treated with a reduced intensity protocol (n=167) whereas patients defined as low risk according to conventional parameters but with a resistant in vitro profile were given intensified therapy (n=47). RESULTS: At a median follow-up of 6.8 years event-free survival was 0.80±0.03 for patients with a sensitive profile, 0.73±0.03 for those with an intermediate profile and 0.67±0.08 for those with a resistant profile (P=0.015). Overall, the treatment results of the cases stratified according to in vitro sensitivity were similar to those of the historical control group stratified based on conventional risk factors. Minimal residual disease at the end of induction was a strong predictor of outcome in B-precursor and T-cell acute lymphoblastic leukemia. There was no correlation between in vitro and in vivo treatment response in B-precursor leukemia (Spearman's r=0.13; P=0.15) in contrast to T-cell acute lymphoblastic leukemia (Spearman's r=0.63; P<0.001) CONCLUSIONS: A moderate reduction in treatment intensity for patients with a sensitive in vitro profile was possible without jeopardizing treatment outcome. However, in vitro drug testing was affected by a decrease in risk predictive power over time and was not correlated with in vivo assessment of minimal residual disease in B-precursor acute lymphoblastic leukemia. It was, therefore, abandoned in favor of the assessment of in vivo response in subsequent CoALL trials.
Authors: G J Kaspers; A J Veerman; R Pieters; C H Van Zantwijk; L A Smets; E R Van Wering; A Van Der Does-Van Den Berg Journal: Blood Date: 1997-10-01 Impact factor: 22.113
Authors: Jianbiao Zhou; Meredith A Goldwasser; Aihong Li; Suzanne E Dahlberg; Donna Neuberg; Hongjun Wang; Virginia Dalton; Kathryn D McBride; Stephen E Sallan; Lewis B Silverman; John G Gribben Journal: Blood Date: 2007-05-07 Impact factor: 22.113
Authors: R Pieters; M L den Boer; M Durian; G Janka; K Schmiegelow; G J Kaspers; E R van Wering; A J Veerman Journal: Leukemia Date: 1998-09 Impact factor: 11.528
Authors: Andrea Pession; Maria Grazia Valsecchi; Giuseppe Masera; Willem A Kamps; Edina Magyarosy; Carmelo Rizzari; Elisabeth R van Wering; Luca Lo Nigro; Anna van der Does; Franco Locatelli; Giuseppe Basso; Maurizio Aricò Journal: J Clin Oncol Date: 2005-10-01 Impact factor: 44.544
Authors: V H J van der Velden; G Cazzaniga; A Schrauder; J Hancock; P Bader; E R Panzer-Grumayer; T Flohr; R Sutton; H Cave; H O Madsen; J M Cayuela; J Trka; C Eckert; L Foroni; U Zur Stadt; K Beldjord; T Raff; C E van der Schoot; J J M van Dongen Journal: Leukemia Date: 2007-02-08 Impact factor: 11.528
Authors: J J van Dongen; T Seriu; E R Panzer-Grümayer; A Biondi; M J Pongers-Willemse; L Corral; F Stolz; M Schrappe; G Masera; W A Kamps; H Gadner; E R van Wering; W D Ludwig; G Basso; M A de Bruijn; G Cazzaniga; K Hettinger; A van der Does-van den Berg; W C Hop; H Riehm; C R Bartram Journal: Lancet Date: 1998-11-28 Impact factor: 79.321
Authors: G L Kaspers; A J Veerman; R Pieters; I van Zantwijk; E Klumper; K Hählen; F C de Waal; E R van Wering Journal: Leukemia Date: 1994-01 Impact factor: 11.528
Authors: G J Kaspers; R Pieters; C H Van Zantwijk; E R Van Wering; A Van Der Does-Van Den Berg; A J Veerman Journal: Blood Date: 1998-07-01 Impact factor: 22.113
Authors: G J Kaspers; R Pieters; C H Van Zantwijk; P A De Laat; F C De Waal; E R Van Wering; A J Veerman Journal: Br J Cancer Date: 1991-09 Impact factor: 7.640
Authors: Franziska Schramm; Udo Zur Stadt; Martin Zimmermann; Norbert Jorch; Arnulf Pekrun; Arndt Borkhardt; Thomas Imschweiler; Holger Christiansen; Jörg Faber; Irene Schmid; Tobias Feuchtinger; Gerhard Beron; Monique L den Boer; Rob Pieters; Martin A Horstmann; Gritta E Janka-Schaub; Gabriele Escherich Journal: Blood Adv Date: 2019-11-26
Authors: Ajay Vora; Anita Andreano; Ching-Hon Pui; Stephen P Hunger; Martin Schrappe; Anja Moericke; Andrea Biondi; Gabriele Escherich; Lewis B Silverman; Nicholas Goulden; Mervi Taskinen; Rob Pieters; Keizo Horibe; Meenakshi Devidas; Franco Locatelli; Maria Grazia Valsecchi Journal: J Clin Oncol Date: 2016-01-11 Impact factor: 44.544
Authors: Yunlei Li; Jessica G C A M Buijs-Gladdines; Kirsten Canté-Barrett; Andrew P Stubbs; Eric M Vroegindeweij; Willem K Smits; Ronald van Marion; Winand N M Dinjens; Martin Horstmann; Roland P Kuiper; Rogier C Buijsman; Guido J R Zaman; Peter J van der Spek; Rob Pieters; Jules P P Meijerink Journal: PLoS Med Date: 2016-12-20 Impact factor: 11.069
Authors: K Canté-Barrett; J A P Spijkers-Hagelstein; J G C A M Buijs-Gladdines; J C M Uitdehaag; W K Smits; J van der Zwet; R C Buijsman; G J R Zaman; R Pieters; J P P Meijerink Journal: Leukemia Date: 2016-04-22 Impact factor: 11.528
Authors: Elisabeth M P Steeghs; Isabel S Jerchel; Willemieke de Goffau-Nobel; Alex Q Hoogkamer; Judith M Boer; Aurélie Boeree; Cesca van de Ven; Marco J Koudijs; Nicolle J M Besselink; Hester A de Groot-Kruseman; Christian Michel Zwaan; Martin A Horstmann; Rob Pieters; Monique L den Boer Journal: Oncotarget Date: 2017-09-16
Authors: Elisabeth M P Steeghs; Judith M Boer; Alex Q Hoogkamer; Aurélie Boeree; Valerie de Haas; Hester A de Groot-Kruseman; Martin A Horstmann; Gabriele Escherich; Rob Pieters; Monique L den Boer Journal: Sci Rep Date: 2019-03-15 Impact factor: 4.379
Authors: Elisabeth M P Steeghs; Marjolein Bakker; Alex Q Hoogkamer; Judith M Boer; Quirine J Hartman; Femke Stalpers; Gabriele Escherich; Valerie de Haas; Hester A de Groot-Kruseman; Rob Pieters; Monique L den Boer Journal: Sci Rep Date: 2018-01-12 Impact factor: 4.379
Authors: I S Jerchel; A Q Hoogkamer; I M Ariës; E M P Steeghs; J M Boer; N J M Besselink; A Boeree; C van de Ven; H A de Groot-Kruseman; V de Haas; M A Horstmann; G Escherich; C M Zwaan; E Cuppen; M J Koudijs; R Pieters; M L den Boer Journal: Leukemia Date: 2017-10-03 Impact factor: 11.528